We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
ARYA Sciences Acquisition Corporation IV | NASDAQ:ARYD | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 11.35 | 11.14 | 11.45 | 2 | 22:04:55 |
Cayman Islands
|
001-40122
|
98-1574672
|
(State or other jurisdiction of incorporation or organization)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
51 Astor Place, 10th Floor
New York, NY
|
10003
|
|
(Address Of Principal Executive Offices)
|
(Zip Code)
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange on
which registered
|
Class A Ordinary Share, $0.0001 par value
|
ARYD
|
The Nasdaq Capital Market
|
Large accelerated filer
|
☐ |
Accelerated filer
|
☐
|
Non-accelerated filer
|
☒ |
Smaller reporting company
|
☒ |
Emerging growth company
|
☒ |
Page
|
||
PART I. FINANCIAL INFORMATION
|
||
Item 1.
|
1
|
|
1
|
||
2
|
||
3
|
||
4
|
||
5
|
||
Item 2.
|
16
|
|
Item 3.
|
21 | |
Item 4.
|
21 | |
PART II. OTHER INFORMATION
|
||
Item 1.
|
22 | |
Item 1A.
|
22 | |
Item 2.
|
23 | |
Item 3.
|
23 | |
Item 4.
|
23 | |
Item 5.
|
23
|
|
Item 6.
|
24 | |
25 |
Item 1. |
Financial Statements
|
June 30,
2022
|
December 31,
2021
|
|||||||
Assets
|
(unaudited) |
|||||||
Current assets:
|
||||||||
Cash
|
$
|
49,535
|
$
|
501,242
|
||||
Prepaid expenses
|
246,400
|
368,797
|
||||||
Total current assets
|
295,935
|
870,039
|
||||||
Investments held in Trust Account
|
149,702,679
|
149,552,336
|
||||||
Total Assets
|
$
|
149,998,614
|
$
|
150,422,375
|
||||
Liabilities and Shareholders’ Deficit
|
||||||||
Current liabilities:
|
||||||||
Accounts payable
|
$
|
67,068
|
$
|
173,073
|
||||
Accrued expenses
|
5,871,543
|
5,812,109
|
||||||
Due to related party
|
30,000
|
-
|
||||||
Total current liabilities
|
5,968,611
|
5,985,182
|
||||||
Deferred underwriting commissions
|
5,232,500
|
5,232,500
|
||||||
Total liabilities
|
11,201,111
|
11,217,682
|
||||||
Commitments and Contingencies
|
||||||||
Class A ordinary shares, $0.0001 par value; 14,950,000 shares subject to possible
redemption at $10.01 and $10.00 per share as of June 30, 2022 and December 31, 2021, respectively
|
149,602,679
|
149,500,000
|
||||||
Shareholders’ Deficit:
|
||||||||
Preference shares, $0.0001 par
value; 1,000,000 shares authorized; none issued or outstanding
|
-
|
-
|
||||||
Class A ordinary shares, $0.0001
par value; 479,000,000 shares authorized; 499,000 shares issued and outstanding as of June 30, 2022
and December 31, 2021, respectively
|
50
|
50
|
||||||
Class B ordinary shares, $0.0001
par value; 20,000,000 shares authorized; 3,737,500 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively
|
374
|
374
|
||||||
Additional paid-in capital
|
-
|
-
|
||||||
Accumulated deficit
|
(10,805,600
|
)
|
(10,295,731
|
)
|
||||
Total shareholders’ deficit
|
(10,805,176
|
)
|
(10,295,307
|
)
|
||||
Total Liabilities and Shareholders’ Deficit
|
$
|
149,998,614
|
$
|
150,422,375
|
For the Three Months Ended
June 30,
|
For the Six Months Ended
June 30,
|
|||||||||||||||
2022 |
2021 |
2022 |
2021 | |||||||||||||
General and administrative expenses
|
$
|
304,811
|
$ | 166,913 | $ | 557,533 | $ | 392,490 | ||||||||
Loss from operations
|
(304,811
|
)
|
(166,913 | ) | (557,533 | ) | (392,490 | ) | ||||||||
Unrealized gain on investments held in Trust Account
|
108,807
|
4,485 | 150,343 | 19,811 | ||||||||||||
Net loss
|
$
|
(196,004
|
)
|
$ | (162,428 | ) | $ | (407,190 | ) | $ | (372,679 | ) | ||||
Basic and diluted weighted average shares outstanding of Class A ordinary shares
|
15,449,000
|
15,449,000 | 15,449,000 | 10,501,848 | ||||||||||||
Basic and diluted net loss per share, Class A ordinary share
|
$
|
(0.01
|
)
|
$ | (0.01 | ) | $ | (0.02 | ) | $ | (0.03 | ) | ||||
Basic and diluted weighted average shares outstanding of Class B ordinary shares
|
3,737,500
|
3,737,500 | 3,737,500 | 3,581,390 | ||||||||||||
Basic and diluted net loss per share, Class B ordinary share
|
$
|
(0.01
|
)
|
$ | (0.01 | ) | $ | (0.02 | ) | $ | (0.03 | ) |
Ordinary Shares | Additional Paid-in
Capital
|
Accumulated
Deficit
|
Total
Shareholders’ Deficit
|
|||||||||||||||||||||||||
Class A
|
Class B
|
|||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
|||||||||||||||||||||||||
Balance - December 31, 2021
|
499,000
|
$
|
50
|
|
3,737,500
|
$
|
374
|
$
|
-
|
$
|
(10,295,731
|
)
|
$
|
(10,295,307
|
)
|
|||||||||||||
Net loss
|
-
|
-
|
-
|
-
|
-
|
(211,186
|
)
|
(211,186
|
)
|
|||||||||||||||||||
Balance - March 31, 2022 (unaudited)
|
499,000
|
$
|
50
|
|
3,737,500
|
$
|
374
|
$
|
-
|
$
|
(10,506,917
|
)
|
$
|
(10,506,493
|
)
|
|||||||||||||
Increase in redemption value of Class A
ordinary shares subject to possible
redemption
|
- | - | - | - | - | (102,679 | ) | (102,679 | ) | |||||||||||||||||||
Net loss |
- | - | - | - | - | (196,004 | ) | (196,004 | ) | |||||||||||||||||||
Balance - June 30, 2022 (unaudited) |
499,000 | $ | 50 | 3,737,500 | $ | 374 | $ | - | $ | (10,805,600 | ) | $ | (10,805,176 | ) |
Ordinary Shares | Additional Paid-in
Capital
|
Accumulated
Deficit
|
Total Shareholders’ Deficit
|
|||||||||||||||||||||||||
Class A
|
Class B
|
|||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
|||||||||||||||||||||||||
Balance - December 31, 2020
|
-
|
$
|
-
|
-
|
$
|
-
|
$
|
-
|
$
|
(13,539
|
)
|
$
|
(13,539
|
)
|
||||||||||||||
Issuance of Class B ordinary shares to Sponsor
|
-
|
-
|
3,737,500
|
374
|
24,626
|
-
|
25,000
|
|||||||||||||||||||||
Sale of private placement shares to Sponsor in
private placement
|
499,000
|
50
|
-
|
-
|
4,989,950
|
-
|
4,990,000
|
|||||||||||||||||||||
Accretion on Class A ordinary shares subject
to possible redemption
|
-
|
-
|
-
|
-
|
(5,014,576
|
)
|
(3,720,320
|
)
|
(8,734,896
|
)
|
||||||||||||||||||
Net loss
|
-
|
-
|
-
|
-
|
-
|
(210,251
|
)
|
(210,251
|
)
|
|||||||||||||||||||
Balance - March 31, 2021 (unaudited)
|
499,000
|
$
|
50
|
3,737,500
|
$
|
374
|
$
|
-
|
$
|
(3,944,110
|
)
|
$
|
(3,943,686
|
)
|
||||||||||||||
Net loss | - | - | - | - | - | (162,428 | ) | (162,428 | ) | |||||||||||||||||||
Balance - June 30, 2021 (unaudited) |
499,000 | $ | 50 | 3,737,500 | $ | 374 | $ | - | $ | (4,106,538 | ) | $ | (4,106,114 | ) |
For the six months ended
June 30,
|
||||||||
Cash Flows from Operating Activities:
|
2022 | 2021 | ||||||
Net loss
|
$
|
(407,190
|
)
|
$ | (372,679 | ) | ||
Unrealized gain on investments held in Trust Account
|
(150,343
|
)
|
(19,811 | ) | ||||
Changes in operating assets and liabilities:
|
||||||||
Prepaid expenses
|
122,397
|
(530,925 | ) | |||||
Accounts payable
|
(106,005
|
)
|
6,500 | |||||
Accrued expenses
|
104,434
|
104,774 | ||||||
Due to related party
|
30,000 | - | ||||||
Net cash used in operating activities
|
(406,707
|
)
|
(812,141 | ) | ||||
Cash Flows from Investing Activities:
|
||||||||
Cash deposited in Trust Account
|
-
|
(149,500,000 | ) | |||||
Net cash used in investing activities
|
-
|
(149,500,000 | ) | |||||
Cash Flows from Financing Activities:
|
||||||||
Proceeds from note payable to related party
|
-
|
127,075 | ||||||
Repayment of note payable to related party
|
-
|
(161,216 | ) | |||||
Proceeds received from initial public offering, gross
|
-
|
149,500,000 | ||||||
Proceeds received from private placement
|
-
|
4,990,000 | ||||||
Offering costs paid
|
(45,000
|
)
|
(3,386,471 | ) | ||||
Net cash (used in) provided by financing activities
|
(45,000
|
)
|
151,069,388 | |||||
Net change in cash
|
(451,707
|
)
|
757,247 | |||||
Cash - beginning of the period
|
501,242
|
- | ||||||
Cash - end of the period
|
$
|
49,535
|
$ | 757,247 | ||||
Supplemental disclosure of noncash investing and financing activities:
|
||||||||
Increase in redemption value of Class A ordinary shares subject to possible redemption
|
$ | 102,679 | $ | - | ||||
Issuance of Class B ordinary shares to Sponsor in exchange for payment of outstanding accounts payable balance
|
$
|
-
|
$ | 25,000 | ||||
Offering costs included in prepaid expenses
|
$
|
-
|
$ | 2,000 | ||||
Offering costs included in accrued expenses
|
$
|
-
|
$ | 70,000 | ||||
Offering costs paid by related party under promissory note
|
$
|
-
|
$ | 22,925 | ||||
Deferred underwriting commissions
|
$
|
-
|
$ | 5,232,500 |
• |
Level 1, defined as observable inputs
such as quoted prices (unadjusted) for identical instruments in active markets;
|
• |
Level 2, defined as inputs other than
quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not
active; and
|
• |
Level 3, defined as unobservable
inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value
drivers are unobservable.
|
For the Three Months Ended
June 30, 2022
|
For the Six Months Ended
June 30, 2022
|
|||||||||||||||
Class A
|
Class B
|
Class A
|
Class B
|
|||||||||||||
Basic and diluted
net income (loss) per common share:
|
||||||||||||||||
Numerator:
|
||||||||||||||||
Allocation of
net income (loss)
|
$
|
(157,823
|
)
|
$
|
(38,181
|
)
|
$
|
(327,870
|
)
|
$
|
(79,320
|
)
|
||||
Denominator:
|
||||||||||||||||
Basic and
diluted weighted average ordinary shares outstanding
|
15,449,000
|
3,737,500
|
15,449,000
|
3,737,500
|
||||||||||||
Basic and diluted
net income (loss) per common share
|
$
|
(0.01
|
)
|
$
|
(0.01
|
)
|
$
|
(0.02
|
)
|
$
|
(0.02
|
)
|
For the Three Months Ended
June 30, 2021
|
For the Six Months Ended
June 30, 2021
|
|||||||||||||||
Class A
|
Class B
|
Class A
|
Class B
|
|||||||||||||
Basic and diluted
net income (loss) per common share:
|
||||||||||||||||
Numerator:
|
||||||||||||||||
Allocation of net
income (loss)
|
$
|
(130,787
|
)
|
$
|
(31,641
|
)
|
$
|
(277,906
|
)
|
$
|
(94,773
|
)
|
||||
Denominator:
|
||||||||||||||||
Basic and diluted
weighted average ordinary shares outstanding
|
15,449,000
|
3,737,500
|
10,501,848
|
3,581,390
|
||||||||||||
Basic and diluted
net income (loss) per common share
|
$
|
(0.01
|
)
|
$
|
(0.01
|
)
|
$
|
(0.03
|
)
|
$
|
(0.03
|
)
|
Gross Proceeds
|
$
|
149,500,000
|
||
Less:
|
||||
Offering costs allocated to Class A ordinary shares subject to possible redemption
|
(8,734,896
|
)
|
||
Plus:
|
||||
Accretion on Class A ordinary shares subject to possible redemption amount
|
8,734,896
|
|||
Increase in redemption value of Class A ordinary shares subject to possible redemption
|
102,679 | |||
Class A ordinary shares subject to possible redemption
|
$
|
149,602,679
|
Description
|
Quoted Prices in
Active Markets
(Level 1)
|
Significant Other
Observable Inputs
(Level 2)
|
Significant Other
Unobservable Inputs
(Level 3)
|
|||||||||
Assets held in Trust Account:
|
||||||||||||
U.S. Treasury Securities
|
$
|
149,697,917
|
$
|
-
|
$
|
-
|
||||||
Cash equivalents - money market
funds
|
4,762 | - | - | |||||||||
$
|
149,702,679
|
$
|
-
|
$
|
-
|
Description
|
Quoted Prices in
Active Markets
(Level 1)
|
Significant Other
Observable Inputs
(Level 2)
|
Significant Other
Unobservable Inputs
(Level 3)
|
|||||||||
Assets held in Trust Account:
|
||||||||||||
U.S. Treasury Securities
|
$
|
149,545,514
|
$
|
-
|
$
|
-
|
||||||
Cash equivalents - money market
funds
|
6,822 | - | - | |||||||||
$
|
149,552,336
|
$
|
-
|
$
|
-
|
Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations.
|
• |
we have no operating history and no revenues, and you have no basis on which to evaluate our ability to achieve our business objective;
|
• |
our ability to select an appropriate target business or businesses;
|
• |
our ability to complete a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”);
|
• |
our expectations around the performance of a prospective target business or businesses;
|
• |
our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial Business Combination;
|
• |
our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial Business Combination;
|
• |
our potential ability to obtain additional financing to complete our initial Business Combination;
|
• |
our pool of prospective target businesses;
|
• |
our ability to consummate an initial Business Combination due to the uncertainty resulting from general economic and political conditions such as recessions, interest rates, international currency fluctuations
and health epidemics and pandemics (including the ongoing COVID-19 pandemic), inflation, changes in diplomatic and trade relationships and acts of war or terrorism;;
|
• |
the ability of our officers and directors to generate a number of potential Business Combination opportunities;
|
• |
our public securities’ potential liquidity and trading;
|
• |
the use of proceeds not held in the trust account or available to us from interest income on the trust account balance;
|
• |
the trust account not being subject to claims of third parties;
|
• |
our financial performance following our initial public offering (the “Initial Public Offering”); and
|
• |
the other risks and uncertainties discussed herein and in our filings with the SEC, including in our Annual Report on Form 10-K filed with the SEC on March 31, 2022.
|
• |
may significantly dilute the equity interest of investors in our Initial Public Offering, which dilution would increase if the anti-dilution provisions in the Class B ordinary shares resulted in the issuance
of Class A ordinary shares on a greater than one-to-one basis upon conversion of the Class B ordinary shares;
|
• |
may subordinate the rights of holders of Class A ordinary shares if preference shares are issued with rights senior to those afforded our Class A ordinary shares;
|
• |
could cause a change in control if a substantial number of our Class A ordinary shares are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and
could result in the resignation or removal of our present officers and directors;
|
• |
may have the effect of delaying or preventing a change of control of us by diluting the share ownership or voting rights of a person seeking to obtain control of us; and
|
• |
may adversely affect prevailing market prices for our Class A ordinary shares.
|
• |
default and foreclosure on our assets if our operating revenues after an initial Business Combination are insufficient to repay our debt obligations;
|
• |
acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or
reserves without a waiver or renegotiation of that covenant;
|
• |
our immediate payment of all principal and accrued interest, if any, if the debt is payable on demand;
|
• |
our inability to obtain necessary additional financing if the debt contains covenants restricting our ability to obtain such financing while the debt is outstanding;
|
• |
our inability to pay dividends on our Class A ordinary shares;
|
• |
using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our Class A ordinary shares if declared, expenses, capital
expenditures, acquisitions and other general corporate purposes;
|
• |
limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate;
|
• |
increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; and
|
• |
limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, execution of our strategy and other purposes and other disadvantages
compared to our competitors who have less debt.
|
Item 3. |
Quantitative and Qualitative Disclosures About Market Risk
|
Item 4. |
Controls and Procedures
|
Item 1. |
Legal Proceedings
|
Item 1A. |
Risk Factors
|
Item 2. |
Unregistered Sales of Equity Securities and Use of Proceeds from Registered Securities.
|
Item 3. |
Defaults upon Senior Securities
|
Item 4. |
Mine Safety Disclosures.
|
Item 5. |
Other Information.
|
Item 6. |
Exhibits.
|
Dated: August 5, 2022
|
ARYA SCIENCES ACQUISITION CORP IV
|
|
By:
|
/s/ Michael Altman
|
|
Name:
|
Michael Altman
|
|
Title:
|
Chief Financial Officer
|
1 Year ARYA Sciences Acquisitio... Chart |
1 Month ARYA Sciences Acquisitio... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions